Trial · NCT05096403
Trial comparisons11
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 11 of 11
Download this page as JSON| Comparison | Source |
|---|---|
| Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Number of Patients Achieving Transfusion Avoidance From Week 5 to Week 24-Part A | Trial comparisons |
Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for ARC Levels-Part A | Trial comparisons |
| Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Normalization of Markers of Hemolysis (ARC) at Week 24-Part A | Trial comparisons |
| Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Normalization of Markers of Hemolysis (LDH) at Week 24-Part A | Trial comparisons |
Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for LDH Levels-Part A | Trial comparisons |
Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Indirect Bilirubin Levels-Part A | Trial comparisons |
| Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Normalization of Markers of Hemolysis (Haptoglobin) at Week 24-Part A | Trial comparisons |
Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Haptoglobin Levels-Part A | Trial comparisons |
| Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Number of Patients Achieving a Response (R) at Week 24 | Trial comparisons |
Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Hemoglobin Levels-Part A | Trial comparisons |
| Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Normalization of Markers of Hemolysis (Indirect Bilirubin) at Week 24-Part A | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05096403/comparisons